In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam–β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model | Zendy

Marguerite L. Monogue | Zendy; Sara Giovagnoli | Zendy; Caterina Bissantz | Zendy; Claudia Zampaloni | Zendy; David P. Nicolau | Zendy

Open Access

In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam–β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model

Author(s) -

Marguerite L. Monogue,

Sara Giovagnoli,

Caterina Bissantz,

Claudia Zampaloni,

David P. Nicolau

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02596-17

Subject(s) - antibiotics , meropenem , urinary system , microbiology and biotechnology , antimicrobial , multiple drug resistance , limiting , in vivo , antibiotic resistance , biology , medicine , drug resistance , intensive care medicine , mechanical engineering , engineering

Urinary tract infections (UTIs) are a tremendous burden on the health care system due to the vast number of infections resulting in antibiotic therapy and/or hospitalization. Additionally, these infections are frequently caused by multidrug-resistant (MDR) organisms, limiting the availability of effective antimicrobials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research